Ryvu Therapeutics S.A. (RVU.WA)
PLN 32.85
(1.39%)
PLN 32.85
(1.39%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 29.3 Million PLN | -630.15% |
| 2022 | 21.39 Million PLN | 942.86% |
| 2021 | -2.53 Million PLN | -138.18% |
| 2020 | 6.64 Million PLN | 113.26% |
| 2019 | -50.15 Million PLN | -205.47% |
| 2018 | 47.55 Million PLN | -23.17% |
| 2017 | 61.89 Million PLN | 97.95% |
| 2016 | 31.26 Million PLN | 19.38% |
| 2015 | 26.19 Million PLN | 36.68% |
| 2014 | 19.16 Million PLN | 168.08% |
| 2013 | 7.14 Million PLN | 93.66% |
| 2012 | 3.69 Million PLN | -39.52% |
| 2011 | 6.1 Million PLN | 3.08% |
| 2010 | 5.92 Million PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -25.21 Million PLN | 13.23% |
| 2024 Q2 | 12 Million PLN | 147.59% |
| 2023 Q2 | 6.3 Million PLN | -14.5% |
| 2023 Q1 | 7.37 Million PLN | -61.83% |
| 2023 FY | -113.44 Million PLN | -630.15% |
| 2023 Q4 | -29.06 Million PLN | -429.77% |
| 2023 Q3 | 8.81 Million PLN | 39.73% |
| 2022 Q3 | 10.53 Million PLN | 341.77% |
| 2022 Q1 | -4 Million PLN | -170.77% |
| 2022 Q2 | -4.35 Million PLN | -8.9% |
| 2022 FY | 21.39 Million PLN | 942.86% |
| 2022 Q4 | 19.32 Million PLN | 83.4% |
| 2021 Q4 | 5.65 Million PLN | 298.5% |
| 2021 Q1 | -4.19 Million PLN | -222.1% |
| 2021 FY | -2.53 Million PLN | -138.18% |
| 2021 Q2 | -1.37 Million PLN | 67.13% |
| 2021 Q3 | -2.84 Million PLN | -106.83% |
| 2020 Q4 | -1.3 Million PLN | 27.69% |
| 2020 FY | 6.64 Million PLN | 113.26% |
| 2020 Q1 | 5.82 Million PLN | 114.44% |
| 2020 Q2 | 4.05 Million PLN | -30.46% |
| 2020 Q3 | -1.79 Million PLN | -144.43% |
| 2019 Q1 | 11.72 Million PLN | 1.99% |
| 2019 Q4 | -40.33 Million PLN | -1009.54% |
| 2019 FY | -50.15 Million PLN | -205.47% |
| 2019 Q3 | -3.63 Million PLN | -126.57% |
| 2019 Q2 | 13.67 Million PLN | 16.72% |
| 2018 Q3 | 12.17 Million PLN | -0.46% |
| 2018 Q4 | 11.49 Million PLN | -5.61% |
| 2018 FY | 47.55 Million PLN | -23.17% |
| 2018 Q2 | 12.23 Million PLN | 4.56% |
| 2018 Q1 | 11.69 Million PLN | -25.36% |
| 2017 FY | 61.89 Million PLN | 97.95% |
| 2017 Q3 | 12.16 Million PLN | -50.77% |
| 2017 Q1 | 9.34 Million PLN | -1.14% |
| 2017 Q2 | 24.71 Million PLN | 164.57% |
| 2017 Q4 | 15.67 Million PLN | 28.79% |
| 2016 Q1 | 8.07 Million PLN | -9.28% |
| 2016 FY | 31.26 Million PLN | 19.38% |
| 2016 Q4 | 9.44 Million PLN | 35.1% |
| 2016 Q3 | 6.99 Million PLN | 3.63% |
| 2016 Q2 | 6.74 Million PLN | -16.39% |
| 2015 Q4 | 8.89 Million PLN | 28.48% |
| 2015 Q3 | 6.92 Million PLN | 31.07% |
| 2015 Q2 | 5.28 Million PLN | 4.01% |
| 2015 Q1 | 5.08 Million PLN | -13.66% |
| 2015 FY | 26.19 Million PLN | 36.68% |
| 2014 Q1 | 3.09 Million PLN | -0.31% |
| 2014 Q4 | 5.88 Million PLN | 10.1% |
| 2014 Q3 | 5.34 Million PLN | 10.38% |
| 2014 Q2 | 4.84 Million PLN | 56.71% |
| 2014 FY | 19.16 Million PLN | 168.08% |
| 2013 Q4 | 3.09 Million PLN | 83.96% |
| 2013 FY | 7.14 Million PLN | 93.66% |
| 2013 Q1 | 1.12 Million PLN | 109.15% |
| 2013 Q2 | 1.23 Million PLN | 9.85% |
| 2013 Q3 | 1.68 Million PLN | 36.19% |
| 2012 Q3 | 1.48 Million PLN | -34.63% |
| 2012 FY | 3.69 Million PLN | -39.52% |
| 2012 Q2 | 2.27 Million PLN | 10.47% |
| 2012 Q1 | 2.05 Million PLN | 0.0% |
| 2012 Q4 | 538.5 Thousand PLN | -63.78% |
| 2011 FY | 6.1 Million PLN | 3.08% |
| 2010 FY | 5.92 Million PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | 2923.108% |
| BIOTON S.A. | 72.85 Million PLN | 59.774% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | -324.663% |
| Mabion S.A. | 114.58 Million PLN | 74.424% |
| Molecure S.A. | -4.1 Million PLN | 814.5% |
| NanoGroup S.A. | -79.01 Thousand PLN | 37188.222% |
| Pharmena S.A. | 5.84 Million PLN | -401.557% |
| Poltreg S.A. | -1.38 Million PLN | 2212.906% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 1238.539% |
| Synthaverse S.A. | 35.16 Million PLN | 16.666% |
| Urteste S.A. | -479 Thousand PLN | 6218.163% |